Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAKI: Nicotinamide in Septic Shock
NCT04589546Phase 3Active, not recruiting
- Sponsor
- CHU Amiens-Picardie
- Start
- Oct 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nicotinamide in acute kidney injury (AKI), sponsored by CHU Amiens-Picardie. Started Oct 2020; status: active, not recruiting.
02
Drugs
nicotinamide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04589546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589546.